HMGB1 and liver dysplastic nodule: To confirm that HMGB1 plays a pathogenic role in DN, we used an efficient and potentially clinically relevant strategy of rHMGB1 A Box administration which competitively antagonizes HMGB1 binding to TLRs and RAGE.